# OnCo record paper-druker-imatinib-phase1-nejm-2001 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-druker-imatinib-phase1-nejm-2001/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-druker-imatinib-phase1-nejm-2001" ;
  schema:name "First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia"@en ;
  schema:description "In the first human study of imatinib, almost every patient with chronic-phase CML who had failed interferon regained normal blood counts, with mild side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-druker-imatinib-phase1-nejm-2001/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJM200104053441401> ;
  schema:sameAs <https://doi.org/10.1056/NEJM200104053441401> ;
  schema:datePublished "2001"^^xsd:gYear ;
  schema:author "Druker BJ, Talpaz M, Resta DJ, et al." ;
  onco:related <https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/> ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-translational-valley/> ;
  onco:journals <https://onco.cc/journals/nejm/> .